• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Guideline of neuropathic pain treatment and dilemma from neurological point of view.
Authors: Yang CM, Chen NC, Shen HC, Chou CH, Yeh PS, Lin HJ, Chang CY, Cheng TJ, Lin KC Abstract Neuropathic pain is a complicated symptomatic disease as migraine in recent years. Not because the pain character differed from the nociceptive inflammatory symptoms but because of its complexity of mechanisms. Though peripheral sensitization, ectopic discharge, central sensitization, central re-organization and loss of inhibition play part of roles in mechanisms, however, based on this mechanistic treatment, the outcome still disappointed physicians and patients, exampled as central post-stroke central pain (CPSP). The...
Source: Acta Neurologica Taiwanica - December 12, 2015 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research

CT diagnostic reference levels based on clinical indications: results of a large-scale European survey
ConclusionsThis is the first study reporting on feasibility of establishing CT DRLs based on CI using European data. Resulting values will serve as a baseline for comparison with local radiological practice, national authorities when DRLs are set/updated, or as a guideline for local DRL establishment.Key Points•First study reporting on the feasibility of establishing CT diagnostic reference levels based on clinical indication using data collected across Europe.•Only one-fourth of the hospitals had CT machines less than 5 years old.•Large dose variations were observed among hospitals and CT protocols were quite differ...
Source: European Radiology - January 15, 2021 Category: Radiology Source Type: research

Diagnostic reference levels and median doses for common clinical indications of CT: findings from an international registry
ConclusionsDRLs for CTDIvol and DLP for EUCLID clinical indications from diverse organizations were established and can contribute to dose optimization. These values were usually significantly higher in the US than in Europe.Key Points•Registry data were used to create benchmarks for 10 common indications for CT identified by the European Society of Radiology.•Observed US radiation doses were higher than European for 9 of 10 indications (except chronic sinusitis).•The presented diagnostic reference levels and median doses highlight potentially unnecessary variation in radiation dose.
Source: European Radiology - October 13, 2021 Category: Radiology Source Type: research

No pain, no gain? Getting the most out of exercise
Staying in shape has all sorts of benefits, from maintaining heart health to warding off dementia and cancerInactivity – fuelled by cars and a sedentary work life – has been dubbed the biggest public health problem of the 21st century, a global pandemic with dramatic impact on peoples wellbeing. The latest reports suggest that around the world it was responsible for 5.3 million deaths in 2008 – around one in 10 – more deaths than smoking.Not only does exercise make you fitter, it can also ward off numerous and often unexpected diseases, from heart attacks, to diabetes, some forms of cancer and dementia. There are t...
Source: Guardian Unlimited Science - January 13, 2014 Category: Science Authors: Catherine de Lange Tags: Cycling Fitness Sport Running Transport Yoga Weightlifting Features UK news Life and style Cycle hire schemes The Observer Swimming Science Source Type: news

Republished: Paget's disease of bone: clinical review and update
Paget's disease (PD) is a focal disorder of bone remodelling that occurs commonly in older people. In this article, we review clinical aspects of PD with an emphasis on recent findings. The epidemiology of PD appears to be changing rapidly, with several groups in different parts of the world reporting a marked reduction in the prevalence and incidence of PD, as well as in the severity of disease seen by clinicians. These findings seem most likely to be caused by changes in exposure to unknown environmental factors that have a role in the development of PD. However, genetic factors are also important. Mutations in SQSTM1 oc...
Source: Postgraduate Medical Journal - May 17, 2014 Category: Journals (General) Authors: Bolland, M. J., Cundy, T. Tags: Pain (neurology), Stroke, Breast cancer, Epidemiology, Calcium and bone Republished best practice Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function.  >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news